Polypill does not slow cognitive decline in older adults at intermediate cardiovascular risk (TIPS-3)

Clinical Question

Does a polypill slow cognitive decline in at-risk older adults?

Bottom line

In this multinational study of adults older than 65 years with intermediate cardiovascular risk, a polypill (40 mg simvastatin, 100 mg atenolol, 25 mg hydrochlorothiazide, and 10 mg ramipril) was no more effective than placebo in slowing the rate of cognitive decline. 1b-

Study design: Randomized controlled trial (double-blinded)

Funding: Industry + govt

Setting: Outpatient (any)

Reviewer

Henry C. Barry, MD, MS
Professor
Michigan State University
East Lansing, MI


Discuss this POEM


Comments

ARUP KUMAR DHARA

Impact assessment

Excellent

Prasanna Yelnadu

May I know Who sponsored this study?

Industry influence has been devastating about which medications we are using in which specialty.
I have learnt from lifestyle medicine that most of the chronic diseases can be reversed in early stages and can be put into remission with an extra effort from physician and patient both. Food is the main source of these diseases. Food industry and pharmaceutical industry ownership have thin lines and mostly owned by same companies. One is feeding the disease and one is treating it and no one is talking about curing it. I feel physicians have become gatekeepers of pharmaceutical industry. Let food be thy medicine… we are forgetting this important fact.

George Manuel Burden

Polypill

That is depressing news. One would think that combination would at least benefit vascular dementia.